GlobalData on MSN13h
How decentralisation can fill the gaps in Alzheimer’s researchAlzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...
News Medical on MSN4h
Finger-Prick Test Brings Alzheimer’s Detection Closer to EveryoneA new Alzheimer’s test collects just a few drops of blood from a finger prick, which can be mailed to a lab for analysis.
Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...
Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...
Worldcrunch on MSN8h
Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...
Lecanemab, a drug designed to slow the progression of early stage Alzheimer's will not be available to patients in Sweden for ...
Viral Chatter on MSN12h
Scientists Link Early Neuron Loss to Alzheimer’s TreatmentsA landmark study examining over 3.4 million brain cells has revealed that Alzheimer’s disease progresses through two distinct ...
Background In the CLARITY AD study, lecanemab was shown to reduce markers of amyloid and slow cognitive decline at 18 months in early Alzheimer’s disease (AD). Here, we report the initial findings ...
Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...
Biogen (BIIB – Research Report) received a Hold rating and price target from Needham analyst Ami Fadia today. The company’s shares closed last Friday at $159.99. Don't Miss our Black Friday Offers: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback